EUVIMEDEUVIMED entdecken
LeserbriefMultizentrische Studie

VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation

Francesco Autore, Daniele Mannina, Federica Lessi, Eugenio Galli, Stefania Oliva, Daniele Derudas, Claudia Giannotta, Claudia Crippa, Katia Mancuso, Magda Marcatti, Idanna Innocenti, Rita Mazza und 2 weitere

Hematological Oncology · 2025

DOI: 10.1002/hon.70049 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Hematological Oncology, 2025. Verfasst von Francesco Autore und 13 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Roma, Italy. Hauptthemen laut MEDLINE: Biomarkers, Peripheral Blood Stem Cell Transplantation, POEMS Syndrome, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overproduction of vascular endothelial growth factor (VEGF) seems to contribute to the pathogenesis, still unclear, of POEMS Syndrome. Our study retrospectively reviewed the clinical and VEGF data from a multicenter Italian cohort of patients affected by POEMS syndrome who underwent to autologous peripheral blood stem cell transplantation (aPBSCT) in order to find an impact on clinical improvement or outcome. Patients with VEGF levels higher than 758 pg/mL were at higher risk of relapse, with sensible difference in PFS ( p = 0.007). VEGF could be used as a marker of relapse and as a marker of disease intensity in patients with POEMS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersPeripheral Blood Stem Cell TransplantationPOEMS SyndromeVascular Endothelial Growth Factor AAdultAgedFemaleHumansMaleMiddle AgedRecurrenceRetrospective StudiesTransplantation, Autologous

Stichwörter der Autor:innen

POEMSVEGFaPBSCT

Substanzen

BiomarkersVascular Endothelial Growth Factor AVEGFA protein, human

Autor:innen und Institutionen

  • Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Roma, Italy.
  • Istituto Clinico Humanitas IRCCS, Rozzano, Italy.
  • Azienda Ospedale Università Padova, Padova, Italy.
  • S. Giovanni Battista, Torino, Italy.
  • SC di Ematologia e CTMO - Oncologico Oncologico di Riferimento Regionale "A. Businco" - ARNAS "G. Brotzu", Cagliari, Italy.
  • ASST Spedali Civili, Brescia, Italy.

Zitieren

APA

Autore, F., Mannina, D., Lessi, F., Galli, E., Oliva, S., Derudas, D., Giannotta, C., Crippa, C., Mancuso, K., Marcatti, M., Innocenti, I., Mazza, R., Bramanti, S., & Laurenti, L. (2025). VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation. Hematological Oncology. https://doi.org/10.1002/hon.70049

Vancouver

Autore F, Mannina D, Lessi F, Galli E, Oliva S, Derudas D, et al. VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation. Hematological Oncology. 2025. doi:10.1002/hon.70049

BibTeX
@article{Autore2025,
  author = {Autore, Francesco and Mannina, Daniele and Lessi, Federica and Galli, Eugenio and Oliva, Stefania and Derudas, Daniele and Giannotta, Claudia and Crippa, Claudia and Mancuso, Katia and Marcatti, Magda and Innocenti, Idanna and Mazza, Rita and Bramanti, Stefania and Laurenti, Luca},
  title = {VEGF as a Relapse Marker and an Intensity of Disease Marker in Patients Affected by POEMS Syndrome Treated With Autologous Peripheral Blood Stem Cell Transplantation},
  journal = {Hematological Oncology},
  year = {2025},
  doi = {10.1002/hon.70049}
}
Kostenlos starten →